Who Exports Captopril from India — 109 Suppliers Behind a $12.4M Market
India's captopril export market is supplied by 109 active exporters who collectively shipped $12.4M across 517 shipments. LINCOLN PHARMACEUTICALS LTD leads with a 63.6% market share, followed by AJANTA PHARMA LIMITED and GRACURE PHARMACEUTICALS LIMITED. The top 5 suppliers together control 83.5% of total export value, reflecting a concentrated market structure.
Top Captopril Exporters from India — Ranked by Export Value
LINCOLN PHARMACEUTICALS LTD is the leading captopril exporter from India, holding a 63.6% share of the $12.4M market across 517 shipments from 109 exporters. The top 5 suppliers — LINCOLN PHARMACEUTICALS LTD, AJANTA PHARMA LIMITED, GRACURE PHARMACEUTICALS LIMITED, BIOMATRIX HEALTHCARE PRIVATE LIMITED, TORRENT PHARMACEUTICALS LTD — collectively control 83.5% of total export value, indicating a highly concentrated market. Individual shares are: LINCOLN PHARMACEUTICALS LTD (63.6%), AJANTA PHARMA LIMITED (10.5%), GRACURE PHARMACEUTICALS LIMITED (5.5%), BIOMATRIX HEALTHCARE PRIVATE LIMITED (2.0%), TORRENT PHARMACEUTICALS LTD (1.9%).
Top Captopril Exporters from India
Ranked by export value · 109 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LINCOLN PHARMACEUTICALS LTD CAPTOPRIL TABLETS BP (23715XCAPTOPRIL TABLETS BP 25 MG AS PER INVCAPTOPRIL TABLETS BP CAPRIL-2572959X10X10 TAB | $7.9M | 2 | 63.6% |
| 2 | AJANTA PHARMA LIMITED CAPTOPRIL TABLETS USP 25MG[5808PACX1X100CAPTOPRIL TABLETS USP 50MG[4104PACX100=4 | $1.3M | 1 | 10.5% |
| 3 | GRACURE PHARMACEUTICALS LIMITED CARDIURINE B/30 TABLETS CAPTOPRIL 50MG 7CARDIURINE B/30 TAB.CAPTOPRIL 50MG+HYDROCHLOROTHIAZIDE 25MG | $686.2K | 1 | 5.5% |
| 4 | BIOMATRIX HEALTHCARE PRIVATE LIMITED CAPTOPRIL TABLETS BP (23715XCAPTOPRIL TABLETS BP 25 MG AS PER INVCAPTOPRIL TABLETS BP CAPRIL-2572959X10X10 TAB | $243.8K | 5 | 2.0% |
| 5 | TORRENT PHARMACEUTICALS LTD ANGIOPRIL 25 TABLET CAPTOPRIL 25MG NOANGIOPRIL 25 TABLETANGIOPRIL 25 TABLET CAPTOPRIL 25MG NOS=10X10 TAB | $235.9K | 4 | 1.9% |
| 6 | STALLION LABORATORIES PVT LTD PHARMACEUTICALS DRUGS & MEDICINES "SATCAPTO-25 "CAPTOPRIL TABLETS BP 25 MG , PACKING : 6PHARMACEUTICALS DRUGS & MEDICINES SATCAPTO-25 TBS | $189.4K | 3 | 1.5% |
| 7 | MEDWISE OVERSEAS PRIVATE LIMITED CAPTOWISE 50 ,CAPTOWISE 25CAPTOWISE 50 | $163.7K | 1 | 1.3% |
| 8 | LINCOLN PHARMACEUTICALS LIMITED CAPTOPRIL TABLETS BP (23715XCAPTOPRIL TABLETS BP 25 MG AS PER INVCAPTOPRIL TABLETS BP CAPRIL-2572959X10X10 TAB | $138.6K | 2 | 1.1% |
| 9 | LARK LABORATORIES (INDIA) LTD CAPTOPRIL TABLETS 25 MGCAPTOPRIL TABLET 25 MG | $94.6K | 1 | 0.8% |
| 10 | AGOG PHARMA LIMITED CAPTOPRIL TABLETS BP (23715XCAPTOPRIL TABLETS BP 25 MG AS PER INVCAPTOPRIL TABLETS BP CAPRIL-2572959X10X10 TAB | $93.5K | 2 | 0.8% |
| 11 | TORRENT PHARMACEUTICALS LIMITED ANGIOPRIL 25 TABLET CAPTOPRIL 25MG NOANGIOPRIL 25 TABLETANGIOPRIL 25 TABLET CAPTOPRIL 25MG NOS=10X10 TAB | $82.9K | 3 | 0.7% |
| 12 | BALAXI PHARMACEUTICALS LIMITED CAPTOPRIL TABLETS 25 MGHARMLESS MEDICINE- CAPTOPRIL 50MG - DAVICAPTOPRIL 25MG TAB | $82.1K | 2 | 0.7% |
| 13 | MICRO LABS LIMITED | $75.6K | 1 | 0.6% |
| 14 | APPLEX PHARMA | $69.6K | 1 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Captopril exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Ajanta Pharma Limited | Approved | Yes | Yes | 27 | Ajanta Pharma operates seven manufacturing facilities in India, with approvals f |
| Torrent Pharmaceuticals Limited | Warning Letter October 20 | Yes | Yes | Not verified | Received FDA warning letter in October 2019; holds WHO-GMP and EU GMP certificat |
| Stallion Laboratories Pvt Ltd | Not Listed | Yes, November 3, 202 | No | Not verified | WHO-GMP certification valid until November 3, 2024. (verification.fda.gov.ph) |
| Micro Labs Limited | Approved | Yes | Yes | Not verified | Micro Labs has FDA approval and holds WHO-GMP and EU GMP certifications. |
| Balaxi Pharmaceuticals Limited | Not Listed | Yes | No | Not verified | Holds WHO-GMP certification; no FDA or EU GMP listings found. |
| Gracure Pharmaceuticals Limited | Not Listed | Yes | No | Not verified | Holds WHO-GMP certification; no FDA or EU GMP listings found. |
| Biomatrix Healthcare Private Limited | Not Listed | Yes | No | Not verified | Holds WHO-GMP certification; no FDA or EU GMP listings found. |
| Lincoln Pharmaceuticals Ltd | Not Listed | Yes | No | Not verified | Holds WHO-GMP certification; no FDA or EU GMP listings found. |
TransData Nexus reviewed the regulatory standing of 8 leading Captopril exporters from India. 2 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 3 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Captopril sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a critical center for API manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses major companies like Zydus Cadila and Torrent Pharmaceuticals. The region's robust infrastructure and regulatory compliance make it a key player in the formulation segment.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for pharmaceuticals. Mumbai, being the financial capital, provides access to international markets, while the surrounding regions host numerous manufacturing units. This strategic location facilitates efficient distribution and export of pharmaceutical products.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub. The region offers tax incentives and has attracted over 1,000 pharmaceutical manufacturing units, including major players like Cipla and Torrent Pharmaceuticals. Baddi's strategic location and favorable policies have made it a cornerstone of India's pharmaceutical manufacturing landscape.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 83.5% of Captopril shipments, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a few sources.
- Engage with Established Manufacturers: Collaborate with leading manufacturers such as Lincoln Pharmaceuticals Ltd and Ajanta Pharma Limited, who have demonstrated significant export volumes and reliability.
- Leverage Regional Specializations: Utilize the strengths of different pharmaceutical clusters—source APIs from Hyderabad and formulations from the Ahmedabad-Vadodara region—to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to international regulatory standards to maintain product quality and facilitate smooth export processes.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Captopril exporters from India
Torrent Pharmaceuticals Ltd. — Torrent Pharma to acquire controlling stake in J.B. Chemicals & Pharmaceuticals
Torrent Pharmaceuticals announced a definitive agreement to acquire a 46.39% equity stake in J.B. Chemicals & Pharmaceuticals from KKR, followed by a merger of the two entities. This strategic move aims to strengthen Torrent's presence in the Indian pharmaceutical market and diversify its healthcare offerings. - IMPACT: The acquisition is expected to enhance Torrent's production capabilities, potentially increasing Captopril exports.
Impact: The acquisition is expected to enhance Torrent's production capabilities, potentially increasing Captopril exports.
Torrent Pharmaceuticals Ltd. — Torrent Pharma receives demand notices totaling Rs 6.63 crore from NPPA
The National Pharmaceutical Pricing Authority (NPPA) issued demand notices to Torrent Pharmaceuticals for alleged overcharging on five drugs between January 2016 and November 2018. The total penalty amounts to over Rs 6.63 crore. Torrent stated that these notices were received on October 3, 2025, and anticipates no material financial impact from this development. - IMPACT: While the financial impact is deemed minimal, regulatory scrutiny may affect Torrent's operational focus, potentially influencing Captopril export activities.
Impact: While the financial impact is deemed minimal, regulatory scrutiny may affect Torrent's operational focus, potentially influencing Captopril export activities.
Torrent Pharmaceuticals Ltd. — Torrent Pharma addresses CDSCO report on flagged drugs
The Central Drugs Standard Control Organisation (CDSCO) listed over 50 drugs as "not of standard quality," including some associated with Torrent Pharmaceuticals. Torrent clarified that the flagged medicines were counterfeit and not manufactured by them, asserting that their products conform to quality standards. - IMPACT: The clarification helps maintain Torrent's reputation, ensuring continued trust in their Captopril exports.
Impact: The clarification helps maintain Torrent's reputation, ensuring continued trust in their Captopril exports.
Common Questions — Captopril Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which captopril supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LINCOLN PHARMACEUTICALS LTD leads with 20 recorded shipments worth $7.9M. AJANTA PHARMA LIMITED (60 shipments) and GRACURE PHARMACEUTICALS LIMITED (31 shipments) are also established high-volume exporters.
Q How many captopril manufacturers are there in India?
India has 109 active captopril exporters with a combined export market of $12.4M across 517 shipments to 63 countries. The top 5 suppliers hold 83.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for captopril from India?
Average FOB unit price: $4.62 per unit, ranging from $0.01 to $352.21. Average shipment value: $24.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 109 verified Indian exporters of Captopril ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 517 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 63 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
517 Verified Shipments
109 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists